Stryker Corporation (SYK) Q4 2022 Earnings Call Transcript

Stryker Corporation (NYSE:SYK) Q4 2022 Earnings Conference Call January 31, 2023 4:30 PM ET

Company Participants

Kevin Lobo - Chair and CEO

Glenn Boehnlein - Chief Financial Officer

Jason Beach - Vice President, Investor Relations

Conference Call Participants

Robbie Marcus - JPMorgan

Matthew O'Brien - Piper Sandler

Vijay Kumar - Evercore

Shagun Singh - RBC

Ryan Zimmerman - BTIG

Vik Chopra - Wells Fargo

Matt Miksic - Barclays

Pito Chickering - Deutsche Bank

Steven Lichtman - Oppenheimer

Drew Ranieri - Morgan Stanley

Michael Matson - Needham & Company

Joanne Wuensch - Citi

Eric Anderson - Cowen

Eric Fleming - Raymond James

Operator

Welcome to the Fourth Quarter and Full Year 2022 Stryker Earnings Call. My name is Tanya, and I will be your operator for today’s call. At this time, all participants are in a listen-only mode. Following the conference, we will conduct a question-and-answer session. This conference call is being recorded for replay purposes.

Before we begin, I would like to remind you that the discussions during this conference call will include forward-looking statements. Factors that could cause actual results to differ materially are discussed in the company’s most recent filings with the SEC.

Also, the discussions will include certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP financial measures can be found in today’s press release that is an exhibit to Stryker’s current report on Form 8-K filed today with the SEC.

I will now turn the call over to Mr. Kevin Lobo, Chair and Chief Executive Officer. You may proceed, sir.

Kevin Lobo

Welcome to Stryker’s fourth quarter earnings call. Joining me today are Glenn Boehnlein, Stryker’s CFO; and Jason Beach, Vice President of Investor Relations. For today’s call, I will provide opening comments, followed by Jason with the trends we saw during the quarter, Mako performance insights and updates on Vocera and Wright Medical. Glenn will then provide additional details regarding our quarterly results and 2023 guidance before we open the call to Q&A.

I will begin with the macroeconomic environment. 2022 was a year where we, alongside many companies, faced unprecedented supply chain challenges and inflationary pressures. We faced these challenges and delivered for over 130 million patients and for our customers all over the world.

We also remain focused on the future, as we progress our pipeline of innovation, enabling a super cycle of new product launches across our portfolio in 2023 and 2024. I want to thank our 50,000 employees for their unrelenting determination and agility.